Oak Ridge, TN – February 14, 2025 — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a groundbreaking case series published in JACC: Case Reports has identified a distinct phenotype in heart failure patients characterized by expanded blood volume overload and elevated red blood cells, opening new avenues for targeted treatment through therapeutic phlebotomy. In the study, researchers evaluated 179 advanced heart failure patients using Daxor’s blood volume analysis (BVA). Through this analysis, they identified thirty-six patients and closely monitored four heart failure cases over a 12-month period, helping to detect an under-recognized condition.

In the clinical case series, titled, “Identification and Treatment of Hypervolemia and Polycythemia in Patients With Advanced Heart Failure,” researchers discovered that 20% (36 patients) exhibited this specific hypervolemia/polycythemia phenotype. Among these cases, four patients were selected for therapeutic phlebotomy based on their functional status and risk factors.

Key Takeaways: 

• BVA detects critical volume issues missed by standard blood tests that drive patient outcomes.
• This condition affects 700,000-1,400,000 US heart failure patients (10-20% of ambulatory cases).
• Patients with this phenotype show worse clinical outcomes than typical heart failure cases.
• Higher stroke and blood clot risks pose additional clinical challenges for these patients if untreated.
• Therapeutic phlebotomy guided by BVA showed significant symptom improvement with zero hospitalizations/deaths over 12 months.